RAMM PHARMA CORP. RAMMF overview

Not for Dissemination in the US or through US Newswire Services TORONTO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “ Company ” or " RAMM") (CSE: RAMM) , is exploring strategic options for the potential sale of its subsidiary, Canapar Corp., and/or its industrial facility located in Ragusa, Italy. This decision is part of RAMM's ongoing efforts to streamline operations and focus on its operating businesses while seeking potential growth...

Not for Dissemination in the US or through US Newswire Services TORONTO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “ Company ” or " RAMM") (CSE: RAMM) , is providing an update on its dispute with Sergio Martines and Naturale Science Inc. (plaintiffs), as previously reported in its press release of May 21 st 2024. The Judge has dismissed the plaintiffs’ claim in the amount of CAD 3,139,931.30 and has awarded Martines CAD 14,971.80 in...

Not for Dissemination in the US or through US Newswire Services TORONTO, May 21, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “ Company ” or " RAMM") (CSE: RAMM) , is providing an update on its dispute with Sergio Martines and NATURALE SCIENCE INC. (together the plaintiffs), the former Chief Executive Officer of Canapar Corp. (“ Canapar ”) and a former director of the Company as reported in its audited financial statements for the year ended...

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM" ) ( CSE: RAMM ), is pleased to advise its shareholders that in accordance with its previously announced strategy of diversifying its product portfolio, in order to reduce its exposure to the strictly regulated environment of Cannabis-based products, it has launched the formulation and production of a full line of botanical-derived food supplements, through its...

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- On September 5th 2023, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “ Company ” or " RAMM") (CSE: RAMM) , announced its intention to complete a non-brokered private placement of up to 20,000,000 units (the “ Units ”) of the Company at a price of $0.05 per Unit for total gross proceeds of up to $1,000,000 (the “ Offering ”). Each Unit would have been comprised of one common share in the capital of the Company (each, a “...

TORONTO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- On September 5th 2023, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “ Company ” or " RAMM") (CSE: RAMM) , announced its intention to complete a non-brokered private placement of up to 20,000,000 units (the “ Units ”) of the Company at a price of $0.05 per Unit for total gross proceeds of up to $1,000,000 (the “ Offering ”). Each Unit would have been comprised of one common share in the capital of the Company (each, a “...

TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “ Company ” or " RAMM ") ( CSE: RAMM ), announces that it has rescinded a grant of 2,000,000 stock options made to the chief operating officer of Canapar Corp., a subsidiary of the Company. About RAMM Pharma Corp. RAMM Pharma is a leader in the field of cannabinoid pharmacology and product formulation for cannabis- based pharmaceuticals and other hemp-based products with a unique and...

TORONTO, Nov. 17, 2023 (GLOBE NEWSWIRE) -- On September 5th 2023, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “ Company ” or " RAMM") (CSE: RAMM) , announced its intention to complete a non-brokered private placement of up to 20,000,000 units (the “ Units ”) of the Company at a price of $0.05 per Unit for total gross proceeds of up to $1,000,000 (the “ Offering ”). Each Unit would have been comprised of one common share in the capital of the Company (each, a “...